Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Uterine Fibroid Embolization Agents Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Uterine Fibroid Embolization Agents Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Gelatin Sponge
      • 1.3.3 Polyvinyl Alcohol (PVA) Particles
      • 1.3.4 Trisacryl Gelatin Microspheres (TAGM)
      • 1.3.5 Polymethyl Methacrylate (PMMA) Microspheres
      • 1.3.6 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global Uterine Fibroid Embolization Agents Market Share by Application (2019-2025)
      • 1.4.2 Clinical Research Institutes
      • 1.4.3 Hospital
      • 1.4.4 Surgical Centers
      • 1.4.5 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Uterine Fibroid Embolization Agents Market Size
      • 2.1.1 Global Uterine Fibroid Embolization Agents Revenue 2014-2025
      • 2.1.2 Global Uterine Fibroid Embolization Agents Sales 2014-2025
    • 2.2 Uterine Fibroid Embolization Agents Growth Rate by Regions
      • 2.2.1 Global Uterine Fibroid Embolization Agents Sales by Regions 2014-2019
      • 2.2.2 Global Uterine Fibroid Embolization Agents Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Uterine Fibroid Embolization Agents Sales by Manufacturers
      • 3.1.1 Uterine Fibroid Embolization Agents Sales by Manufacturers 2014-2019
      • 3.1.2 Uterine Fibroid Embolization Agents Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Uterine Fibroid Embolization Agents Revenue by Manufacturers (2014-2019)
      • 3.2.2 Uterine Fibroid Embolization Agents Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Uterine Fibroid Embolization Agents Market Concentration Ratio (CR5 and HHI)
    • 3.3 Uterine Fibroid Embolization Agents Price by Manufacturers
    • 3.4 Key Manufacturers Uterine Fibroid Embolization Agents Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Uterine Fibroid Embolization Agents Market
    • 3.6 Key Manufacturers Uterine Fibroid Embolization Agents Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Gelatin Sponge Sales and Revenue (2014-2019)
      • 4.1.2 Polyvinyl Alcohol (PVA) Particles Sales and Revenue (2014-2019)
      • 4.1.3 Trisacryl Gelatin Microspheres (TAGM) Sales and Revenue (2014-2019)
      • 4.1.4 Polymethyl Methacrylate (PMMA) Microspheres Sales and Revenue (2014-2019)
      • 4.1.5 Others Sales and Revenue (2014-2019)
    • 4.2 Global Uterine Fibroid Embolization Agents Sales Market Share by Type
    • 4.3 Global Uterine Fibroid Embolization Agents Revenue Market Share by Type
    • 4.4 Uterine Fibroid Embolization Agents Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Uterine Fibroid Embolization Agents Sales by Application

    6 United States

    • 6.1 United States Uterine Fibroid Embolization Agents Breakdown Data by Company
    • 6.2 United States Uterine Fibroid Embolization Agents Breakdown Data by Type
    • 6.3 United States Uterine Fibroid Embolization Agents Breakdown Data by Application

    7 European Union

    • 7.1 European Union Uterine Fibroid Embolization Agents Breakdown Data by Company
    • 7.2 European Union Uterine Fibroid Embolization Agents Breakdown Data by Type
    • 7.3 European Union Uterine Fibroid Embolization Agents Breakdown Data by Application

    8 China

    • 8.1 China Uterine Fibroid Embolization Agents Breakdown Data by Company
    • 8.2 China Uterine Fibroid Embolization Agents Breakdown Data by Type
    • 8.3 China Uterine Fibroid Embolization Agents Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Uterine Fibroid Embolization Agents Breakdown Data by Company
    • 9.2 Rest of World Uterine Fibroid Embolization Agents Breakdown Data by Type
    • 9.3 Rest of World Uterine Fibroid Embolization Agents Breakdown Data by Application
    • 9.4 Rest of World Uterine Fibroid Embolization Agents Breakdown Data by Countries
      • 9.4.1 Rest of World Uterine Fibroid Embolization Agents Sales by Countries
      • 9.4.2 Rest of World Uterine Fibroid Embolization Agents Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Astellas Pharma
      • 10.1.1 Astellas Pharma Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Uterine Fibroid Embolization Agents
      • 10.1.4 Uterine Fibroid Embolization Agents Product Introduction
      • 10.1.5 Astellas Pharma Recent Development
    • 10.2 Nippon Kayaku
      • 10.2.1 Nippon Kayaku Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Uterine Fibroid Embolization Agents
      • 10.2.4 Uterine Fibroid Embolization Agents Product Introduction
      • 10.2.5 Nippon Kayaku Recent Development
    • 10.3 Pfizer
      • 10.3.1 Pfizer Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Uterine Fibroid Embolization Agents
      • 10.3.4 Uterine Fibroid Embolization Agents Product Introduction
      • 10.3.5 Pfizer Recent Development
    • 10.4 Boston Scientific Corporation
      • 10.4.1 Boston Scientific Corporation Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Uterine Fibroid Embolization Agents
      • 10.4.4 Uterine Fibroid Embolization Agents Product Introduction
      • 10.4.5 Boston Scientific Corporation Recent Development
    • 10.5 Merit Medical Systems
      • 10.5.1 Merit Medical Systems Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Uterine Fibroid Embolization Agents
      • 10.5.4 Uterine Fibroid Embolization Agents Product Introduction
      • 10.5.5 Merit Medical Systems Recent Development
    • 10.6 Cook Medical
      • 10.6.1 Cook Medical Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Uterine Fibroid Embolization Agents
      • 10.6.4 Uterine Fibroid Embolization Agents Product Introduction
      • 10.6.5 Cook Medical Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Uterine Fibroid Embolization Agents Sales Channels
      • 11.2.2 Uterine Fibroid Embolization Agents Distributors
    • 11.3 Uterine Fibroid Embolization Agents Customers

    12 Market Forecast

    • 12.1 Global Uterine Fibroid Embolization Agents Sales and Revenue Forecast 2019-2025
    • 12.2 Global Uterine Fibroid Embolization Agents Sales Forecast by Type
    • 12.3 Global Uterine Fibroid Embolization Agents Sales Forecast by Application
    • 12.4 Uterine Fibroid Embolization Agents Forecast by Regions
      • 12.4.1 Global Uterine Fibroid Embolization Agents Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Uterine Fibroid Embolization Agents Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Uterine fibroid embolization (UFE) is an effective, non-surgical method used to treat uterine fibroids in the fertile women population. It is performed with the help of uterine fibroid embolization agents, delivered to the tumor by micro-catheters. The embolization agents block the arteries supplying blood to the tumor and force them to shrink.
      The increased awareness about the uterine fibroids amongst women and popularity of minimally invasive procedure will drive the global market for uterine fibroid embolization agents. In addition, the fact that UFE allows woman to preserve their uterus, otherwise not possible with full or even partial hysterectomy will further drive the market.
      In 2019, the market size of Uterine Fibroid Embolization Agents is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Uterine Fibroid Embolization Agents.

      This report studies the global market size of Uterine Fibroid Embolization Agents, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Uterine Fibroid Embolization Agents sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Astellas Pharma
      Nippon Kayaku
      Pfizer
      Boston Scientific Corporation
      Merit Medical Systems
      Cook Medical
      ...

      Market Segment by Product Type
      Gelatin Sponge
      Polyvinyl Alcohol (PVA) Particles
      Trisacryl Gelatin Microspheres (TAGM)
      Polymethyl Methacrylate (PMMA) Microspheres
      Others

      Market Segment by Application
      Clinical Research Institutes
      Hospital
      Surgical Centers
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Uterine Fibroid Embolization Agents status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Uterine Fibroid Embolization Agents manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Uterine Fibroid Embolization Agents are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now